Immunotherapy's new prospects and clinical difficulties in BRAF-mutated acral melanoma.
0/5 보강
APA
He K, Fang M, Cao Y (2025). Immunotherapy's new prospects and clinical difficulties in BRAF-mutated acral melanoma.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70082
MLA
He K, et al.. "Immunotherapy's new prospects and clinical difficulties in BRAF-mutated acral melanoma.." Journal of the European Academy of Dermatology and Venereology : JEADV, 2025.
PMID
41109969 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Discovery of potent kinase inhibitors with improved pharmacokinetics and safety potentials through structural optimization of dasatinib.
- Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).
- Diagnostic challenges in hepatic metastatic olfactory neuroblastoma: a case report and literature review.
- Cinnamic Acid Ameliorates Myocardial Injury Caused by Arsenic Trioxide in Rats by Modulating Oxidative Stress and Inflammatory Response.
- Identifying genes associated with Sorafenib resistance in hepatocellular carcinoma to develop risk model.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.
- A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAF Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.
- Exploring Gallium(III) Complexes as Emerging Therapeutic Candidates for Breast Cancer.
- Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.
- Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol.